MiMedx to acquire Sanara MedTech for $35 per share

MiMedx Group Inc. announced a definitive agreement to acquire Sanara MedTech for $35 per share in an all-stock deal. Sanara is a wound care and surgical products company with more than $100 million in trailing revenue, primarily from its CellerateRX product line. The combination is expected to add roughly $4 billion in addressable market and generate at least $20 million in annual synergies, with pro forma 2027 revenue projected above $400 million. MiMedx will issue approximately 4.2 million shares to fund the acquisition and secured a $300 million term loan for financing.